We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Clinical Updates

Divergent Microbial Mechanisms and Predictive Signatures in Necrotising Enterocolitis: The Role of Gut Phages and Bacterial Resistomes

MedXY Editorial Team•Sep 23, 2026•Clinical Updates
gut microbiomebacterial resistomephagesnecrotising enterocolitis

Highlights

  • Distinct gut phageome dynamics precede early-onset NEC, characterized by lysogenic prophage signatures stabilizing pathobionts.
  • Bacterial resistome profiles, particularly antimicrobial resistance gene patterns, robustly predict late-onset NEC risk.
  • Integrated metagenomic-metatranscriptomic and machine learning approaches enable early, non-invasive NEC risk stratification.
  • These findings reveal polymicrobial etiologies with clinical implications for targeted prevention and microbiome-modulating therapies.

Background

Necrotising enterocolitis (NEC) remains one of the most severe gastrointestinal emergencies in preterm infants, with a multifactorial pathogenesis involving aberrant microbial colonization, immature intestinal barriers, and dysregulated host immune responses. Despite decades of research, reliable early clinical or laboratory predictors for NEC remain elusive, hindering timely interventions. Emerging evidence implicates the gut microbiome, not only bacterial communities but also their viral constituents (particularly bacteriophages prophages), as critical determinants in NEC development. The neglect of the virome and oversimplified models focusing solely on bacterial dysbiosis have limited progress in predictive biomarker discovery and mechanistic understanding. This review synthesizes recent high-quality evidence, emphasizing the roles of gut phages (prophageomes) and bacterial resistomes in NEC pathogenesis and prediction, aiming to inform clinical risk stratification and novel therapeutic strategies.

Key Content

Evolution of Microbiome Research in NEC

Initial studies focusing on bacterial taxonomic shifts identified associations between NEC and blooms of specific taxa such as Proteobacteria, but lacked reproducibility and causality. More refined approaches incorporated functional metagenomics, revealing microbial metabolic disruptions implicated in mucosal injury. However, the role of resident gut phages, particularly temperate prophages integrated into bacterial genomes, emerged only recently as studies utilizing metagenomic sequencing uncovered complex phage-bacteria interactions influencing microbial community stability and pathogenic potential.

Role of Gut Phages in NEC: Insights from Integrated Metagenomics and Metatranscriptomics

The landmark study by Zhang et al. (2026) conducted longitudinal, integrated metagenomic and metatranscriptomic analyses of 1825 stool samples from 129 preterm infants across three US NICUs, including 43 NEC cases and matched controls. They demonstrated distinct viral diversity trajectories pre-NEC onset, especially in early-onset cases (≤40 days), where signatures of phage-bacterial interactions predicted NEC with 75% accuracy and 81% sensitivity.

Metatranscriptomic data revealed a paradoxical increase of phage DNA abundance concurrent with low phage gene expression prior to NEC episodes, suggesting a lysogenic phage lifecycle predominance. This lysogeny may confer fitness advantages to pathobionts by encoding auxiliary metabolic genes that enhance resilience under antibiotic exposure and inflammatory stress. These prophage-encoded functions potentially stabilize virulent bacteria, facilitating mucosal injury. Such insights elucidate phages as active modulators, not mere bystanders, in NEC pathogenesis.

Bacterial Resistomes and Late-Onset NEC Prediction

Late-onset NEC (>40 days postnatal age) was best predicted by antibacterial resistome profiles, with machine learning models achieving 83% accuracy. This underscores the role of antibiotic resistance gene carriage and potential microbiome perturbations driven by antimicrobial exposure in selecting pathogenic bacterial communities.

This finding aligns with observational studies linking prolonged or broad-spectrum antibiotic use to NEC risk, likely mediated via selection pressure promoting expansion of resistant pathobionts. Resistome profiling thus emerges as a clinically relevant biomarker to identify infants at heightened risk and guide antibiotic stewardship policies.

Polymicrobial Aetiologies and Stratified Disease Mechanisms

The divergent microbial preludes—phage-driven early NEC versus resistome-associated late NEC—highlight polymicrobial etiologies with distinct temporal mechanistic pathways. Early disease pathogenesis involves phage-mediated modulation of bacterial communities, possibly influencing initial mucosal barrier compromise. Late disease relates more to antibiotic resistance and dysbiosis-driven inflammation.

Considering disease heterogeneity by onset timing enables refined risk stratification and tailored interventions, diverging from the earlier one-size-fits-all prevention approaches such as universal probiotic administration.

Methodological Advances and Machine Learning Integration

Zhang et al.’s approach combining longitudinal multi-omic data with robust machine learning classifiers exemplifies methodological progress that overcomes challenges of ecological complexity and temporal dynamics in NEC microbiome research. These analytic frameworks allow integration of prenatal, perinatal and postnatal exposures (antibiotics, nutrition, pharmacotherapies) with microbial ecosystem changes, enhancing predictive model performance and interpretability.

The study also highlights the potential of metatranscriptomics to distinguish phage lifecycle states, an innovative biomarker dimension previously unexplored in NEC.

Expert Commentary

NEC prediction and prevention remain high priorities in neonatology. This emerging evidence redefines the microbial framework contributing to NEC, emphasizing the importance of considering the virome and resistome alongside classical bacteriome analyses. The demonstration of prophages as active modulators regulating pathobiont dynamics offers a paradigm shift with significant translational implications.

Clinically, early identification of infants with pre-symptomatic phage signatures may enable targeted surveillance and judicious immunomodulatory interventions. For late-onset NEC, resistome-informed antibiotic stewardship could reduce risk by preserving microbial ecosystem balance.

Nevertheless, challenges persist. The complexity of virome detection, standardization of multi-omic techniques, and generalizability across diverse neonatal populations require further validation. Also, it remains to be determined whether manipulating prophage dynamics or resistomes can be safely achieved through therapeutics such as phage therapy, fecal microbiota transplantation, or selective antibiotic regimens.

Current neonatal practice guidelines (e.g., American Academy of Pediatrics, European Society for Paediatric Gastroenterology Hepatology and Nutrition) have yet to integrate virome or resistome markers due to limited clinical validation. Ongoing prospective multicenter studies incorporating multi-omic platforms and real-time analytics promise to fill these gaps.

Conclusion

Recent integrated metagenomic and metatranscriptomic research with machine learning delineates divergent microbial preludes to NEC, defined by gut phages in early-onset disease and bacterial resistomes in late-onset cases. These findings enrich understanding of NEC’s polymicrobial etiologies and present promising avenues for early, non-invasive prediction and microbiome-targeted preventive strategies.

Future research priorities include standardizing virome-resistome profiling, validating predictive biomarkers in larger cohorts, and assessing therapeutic interventions targeting the prophageome and resistome. Translation of these insights into clinical protocols could ultimately reduce NEC incidence, severity, and lifelong morbidity in vulnerable preterm infants.

References

  • Zhang K, Gorelik MG, Sullivan JE, Radmacher P, Escobedo M, Warner BB, Tarr PI, Dantas G. Divergent microbial preludes to necrotising enterocolitis defined by gut phages and bacterial resistomes. Gut. 2026 Sep 16. PMID: 42749360.
  • Pammi M, Cope J, Tarr PI, Warner BB, Morrow AL, Mai V, Gregory KE, McMurtry V, Ferris MJ, Saiman L. Intestinal dysbiosis in preterm infants preceding necrotizing enterocolitis: a systematic review and meta-analysis. Microbiome. 2017;5(1):31. PMID: 28399984.
  • Mai V, Young CM, Ukhanova M, Wang X, Sharma R, Hudak M, George JR, Li N, Neu J. Fecal microbiota in premature infants prior to necrotizing enterocolitis. PLoS One. 2011;6(6):e20647. PMID: 21647457.
  • Norman JM, Handley SA, Baldridge MT, Droit L, Liu CY, Keller BC, Kambal A, Monaco CL, Zhao G, Fleshner P, et al. Disease-specific alterations in the enteric virome in inflammatory bowel disease. Cell. 2015;160(3):447-460. PMID: 25594194.
  • Rea MC, Dobson A, O’Sullivan O, Crispie F, Fouhy F, Cotter PD, Ross RP, Hill C. Microbial-mediated protection against intestinal infection: mount a good offense to protect the gut. J Physiol. 2016;594(17):4849-4861. PMID: 27301836.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Distinct Gut Microbiome Signatures Predict Short-term Hospitalisation Risk in Cirrhosis: Insights from a Global Metagenomic StudyThis multinational study reveals that specific gut microbiome profiles significantly correlate with 90-day hospitalisation risk in cirrhosis, enhancing prognostic accuracy beyond clinical features alone.Sep 27, 2026Dynamic Gut Microbiome Changes Enhance Immunotherapy Outcomes in Advanced Liver CancerThis longitudinal study reveals that gut microbiome remodeling during immune checkpoint inhibitor therapy in advanced liver cancer patients predicts clinical benefit, improving biomarker accuracy and survival stratification.Sep 21, 2026Early Childhood Exposure to Crohn’s Disease-Affected Siblings: Implications for Gut Microbiome and Disease SusceptibilityChildhood exposure to siblings with Crohn’s disease significantly raises disease risk, linked to distinct gut microbiome changes that may drive disease onset through immune modulation.Aug 28, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Fecal Microbiota Transplantation: A Promising Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease
This retrospective multicenter study evaluates fecal microbiota transplantation (FMT) for steroid-refractory acute graft-versus-host disease (aGvHD), demonstrating a 60.5% response at day 28 and highlighting FMT’s potential as a safe
Aug 27, 2026
Fecal Short-Chain Fatty Acids in Mother-Infant Dyads: No Direct Link to Islet Autoimmunity DevelopmentA longitudinal study shows no association between fecal short-chain fatty acid levels during pregnancy and early childhood with the progression to islet autoimmunity in children at risk for type 1 diabetes.Aug 25, 2026
Fermentable Fiber Subtypes in Crohn’s Disease: From Primary Prevention to Mechanistic Regulation of the Gut-Immune AxisRecent multi-omic and clinical evidence suggests that specific fermentable fibers, particularly β-glucan and inulin, significantly reduce Crohn’s Disease risk in high-risk individuals by preserving gut barrier function and modulating Jun 1, 2026